Reviva Pharmaceuticals I... (RVPH)
NASDAQ: RVPH
· Real-Time Price · USD
0.46
-0.05 (-10.63%)
At close: Aug 27, 2025, 3:59 PM
-10.63% (1D)
| Bid | 0.46 |
| Market Cap | 31.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.11M |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -0.72 |
| Forward PE | -1.01 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.52 |
| Volume | 2,100,509 |
| Avg. Volume (20D) | 2,552,515 |
| Open | 0.52 |
| Previous Close | 0.51 |
| Day's Range | 0.46 - 0.52 |
| 52-Week Range | 0.30 - 4.28 |
| Beta | -0.05 |
| Ex-Dividend Date | n/a |
About RVPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RVPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RVPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
Reviva Pharmaceuticals Holdings shares are trading...
Unlock content with
Pro Subscription
3 months ago
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced a $10 million public offering of 20 million shares and dual warrants at a combined price of $0.50 per share and accompanying warrants.
9 months ago · seekingalpha.com
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is LowReviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announc...